News Daily News Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data L.A. McKeown July 24, 2025
News Daily News Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds Michael O'Riordan April 25, 2025
News Daily News REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF Michael O'Riordan March 11, 2025
News Daily News Sotagliflozin Reduces Ischemic Risk in SCORED Analysis Yael L. Maxwell February 25, 2025
News Daily News Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations L.A. McKeown January 31, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Daily News Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes Michael O'Riordan August 19, 2024
News Daily News CMS Announces Negotiated Medicare Prices for First 10 Drugs Yael L. Maxwell August 16, 2024
News Daily News Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors Yael L. Maxwell August 15, 2024
News Daily News Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF Michael O'Riordan July 26, 2024
News Daily News ICD Benefits Hold Up for Modern-day Primary Prevention, but Questions Remain Todd Neale March 25, 2024
News Daily News Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds L.A. McKeown February 23, 2024
News Daily News First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists L.A. McKeown August 31, 2023
News Daily News SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients Todd Neale July 17, 2023
News Daily News Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF Todd Neale March 15, 2023
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022